Anidulafungin is a semisynthetic echinocandin used as an antifungal drug.
Anidulafungin was originally manufactured and submitted for FDA approval by ...
ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion
that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic ...
Anidulafungin is a semisynthetic product of echinocandin B, itself a fermentation
product of the mold Aspergillus nidulans. It was developed by Eli Lily, ...
Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained
approval by the Food and Drug Administration (FDA) in February 21, 2006; ...
Jun 24, 2016 ... Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of
cytochrome P450 isoenzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A).
Anidulafungin (Eraxis; Pfizer) is the newest echinocandin antifungal to be
approved by the US Food and Drug Administration for the treatment of
Package Insert for ERAXIS (anidulafungin) for Injection ... The pharmacokinetics
of anidulafungin following IV administration have been characterized in.
Anidulafungin, a new echinocandin, has potent activity against candida species.
We compared anidulafungin with fluconazole in a randomized, double-blind, ...
Echinocandins represent the newest class of antifungal agents. Currently, three
echinocandins, anidulafungin, caspofungin and micafungin are licensed for ...
The echinocandin anidulafungin is an effective alternative to fluconazole,
demonstrating superiority to fluconazole for the treatment of C/IC in a pivotal